NASDAQ : OMER
Omeros Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 18.18 USD (Oct 30, 2026, 3:13 PM EDT) · Market cap 1.32B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.33B |
| Enterprise Value | 1.50B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 72.39M |
| Shares Outstanding | 72.39M |
| Shares Change (YoY) | +36.36% |
| Shares Change (QoQ) | -0.54% |
| Owned by Insiders (%) | 4.29% |
| Owned by Institutions (%) | 50.30% |
| Float | 69.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 11.74 |
| Forward PE | 19.21 |
| PS Ratio | 34.74 |
| Forward PS | 14.99 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 12.01 |
| EV / Sales | 39.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.95 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.20 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.68% |
| Return on Invested Capital (ROIC) | -34.18% |
| Return on Capital Employed (ROCE) | -37.95% |
| Weighted Average Cost of Capital (WACC) | 15.58% |
| Revenue Per Employee | $219,554 |
| Profits Per Employee | $713,291 |
| Employee Count | 175 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.10M |
| Effective Tax Rate | 1.77% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.57 |
| 52-Week Price Change | +140.10% |
| 50-Day Moving Average | 18.52 |
| 200-Day Moving Average | 13.49 |
| Relative Strength Index (RSI) | 53.58 |
| Average Volume (20 Days) | 1,163,915 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.43M |
| Short Previous Month | 11.38M |
| Short % of Shares Out | 15.79% |
| Short % of Float | 16.50% |
| Short Ratio (days to cover) | 8.63 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 38.42M |
| Gross Profit | 14.73M |
| Operating Income | -72.82M |
| Pretax Income | 118.63M |
| Net Income | 124.83M |
| EBITDA | -71.91M |
| EBIT | -72.82M |
| Earnings Per Share (EPS) | $1.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 131.95M |
| Total Debt | 296.87M |
| Net Cash | -164.92M |
| Net Cash Per Share | -$2.28 |
| Equity (Book Value) | -51.35M |
| Book Value Per Share | -0.71 |
| Working Capital | 90.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -68.67M |
| Capital Expenditures | -56,000 |
| Depreciation & Amortization | 907,000 |
| Net Borrowing | -84.83M |
| Free Cash Flow | -68.73M |
| FCF Per Share | -$0.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | 38.34% |
| Operating Margin | -189.53% |
| Pretax Margin | 308.76% |
| Profit Margin | 324.88% |
| EBITDA Margin | -187.17% |
| EBIT Margin | -189.53% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.36% |
| Shareholder Yield | -36.36% |
| Earnings Yield | 8.52% |
| FCF Yield | -5.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.50 |
| Price Target Difference | 49.13% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | -3.20% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.32 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |